pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

605 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1013Endpoints769BioPharma Dive293BioSpace207Fierce Biotech197onclive165raps74globenewswire health73
therapy area
allOncology5926Rare Disease1357Cardiology1077Hematology1007Immunology988Pulmonology891Vaccines
  • Lilly buys non-opioid pain drugmaker 4E
    It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.
    BioPharma Dive · 2mo ago↗ source
  • Express Scripts, PCMA sue to block Tennesee law breaking up PBMs and pharmacies
    Express Scripts and the PBM lobby are following in CVS Caremark’s footsteps in filing complaints challenging the FAIR Rx Act, which was passed earlier this year despite vehement opposition from PBMs.
    BioPharma Dive · 2mo ago↗ source
  • FDA staff scrutinizes evidence supporting Moderna’s flu vaccine
    Ahead of a Thursday advisory panel meeting, agency scientists highlighted shortcomings in data accrued for a vaccine the FDA controversially refused to even review earlier this year.
    BioPharma Dive
← prev
page 13 of 25
next →
fda recalls47
fda medwatch36
fda press28
885
Psychiatry & CNS707
Ophthalmology416
Pain371
Endocrinology & Metabolism370
Infectious Disease345
· 2mo ago
↗ source
  • Edgewise heart drug passes key trial test
    Still, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy medicines from Bristol Myers Squibb and Cytokinetics.
    BioPharma Dive · 2mo ago↗ source
  • Neumora depression drug fails; EnGene to cut 50% of staff
    Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.
    BioPharma Dive · 2mo ago↗ source
  • Medicare drug price rule may target under-the-skin Keytruda and Opdivo
    For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.
    BioPharma Dive · 2mo ago↗ source
  • Lilly scores early positive data for new JAK drug
    Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.
    BioPharma Dive · 2mo ago↗ source
  • J&J multiple myeloma drug gains edge in earlier stage disease
    The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.
    BioPharma Dive · 2mo ago↗ source
  • Celiac disease is entering a new era of therapeutic innovation
    For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.
    BioPharma Dive · 2mo ago↗ source
  • Planning a successful pivot from lab to clinic
    For sterile injectables, key early decisions can have a significant impact on the products’ development.
    BioPharma Dive · 2mo ago↗ source
  • Rapport ‘fully prepared’ to launch seizure drug solo, CEO says
    In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.
    BioPharma Dive · 2mo ago↗ source
  • Summit pulls $500M share sale a day after announcing it
    The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.
    BioPharma Dive · 2mo ago↗ source
  • Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
    A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.
    BioPharma Dive · 2mo ago↗ source
  • Novartis RNA drug acquired in $12B Avidity deal notches a trial win
    The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
    BioPharma Dive · 2mo ago↗ source
  • J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
    New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
    BioPharma Dive · 2mo ago↗ source
  • Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
    The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
    BioPharma Dive · 2mo ago↗ source
  • Ethyreal starts up with $101M and takes aim at a pair of immune diseases
    The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
    BioPharma Dive · 2mo ago↗ source
  • Sanofi stops immune drug trial in latest research setback
    The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.
    BioPharma Dive · 2mo ago↗ source
  • Parabilis sets a record with a $670M biotech IPO
    The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.
    BioPharma Dive · 2mo ago↗ source
  • AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
    Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell…
    BioPharma Dive · 2mo ago↗ source
  • Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
    Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
    BioPharma Dive · 2mo ago↗ source
  • Stealthy startup Treeline plans a reverse merger
    Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
    BioPharma Dive · 2mo ago↗ source
  • GSK boosts cancer pipeline with $11B Nuvalent buyout
    The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.
    BioPharma Dive · 2mo ago↗ source
  • City banks nearly $100M for next-gen RNAi drugs
    Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.
    BioPharma Dive · 2mo ago↗ source
  • Roche stakes $700M on Nurix’s protein-degrading drug
    Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.
    BioPharma Dive · 2mo ago↗ source